ClinicalTrials.gg
RecruitingNCT07594860POTATO-2Updated Oct 28, 2026

Effect of a Probiotic or Postbiotic on Gut Microbiome During Antibiotic Treatment

An interventional study of Probiotic and Postbiotic in Microbiome, sponsored by The Archer-Daniels-Midland Company. Recruiting at 1 site in Greece. Open to participants aged 18 Years to 65 Years, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-28.

Sponsored by The Archer-Daniels-Midland Company · Not applicable, Interventional, and Prevention

How we know

From the registry’s dates

  • Started Aug 2026; still recruiting 2 months later.
Updated Oct 28, 2026Now RecruitingSite recruiting status changed+1 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
126
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Study summary

This study assesses the effects of a probiotic or postbiotic on gut microbiome during antibiotic treatment.

Read the detailed description

The current study aims to assess the changes in microbiome composition in healthy adults receiving antibiotic treatment, and concomitantly a probiotic or postbiotic. The trial will be run in Greece, and will recruit healthy adults from the general population.

02

Conditions studied

  • Microbiome

Browse trials for

Keywords

  • Antibiotic
  • Dysbiosis
  • Microbiome composition
  • Antibiotic Resistance Genes
  • Microbiome Recovery
  • Antibiotic Scarring
  • Probiotic
  • Postbiotic
03

In context

Dysbiosis

190 studies on the registry are indexed under Dysbiosis; 67 are open to participants now.

This study's planned enrollment of 126 is above the median of 60 across 134 interventional studies indexed under Dysbiosis.

Browse Dysbiosis studies →

Lead sponsor

The Archer-Daniels-Midland Company is the lead sponsor of 19 studies on the registry; 6 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Participants meeting ALL of the following criteria will be recruited for the study:

  • Males and females aged ≥18 to ≤ 65 years; if female, either not of or using a medically approved method of and willing to take a pregnancy test at screening.
  • (BMI) 18.5-29.9 kg/m².
  • Healthy as determined by medical history and physical examination.
  • Agreed not to change current dietary habits during the course of the study.
  • Able to attend study visits, comply with study requirements (consumption of study medications, especially biological sample collection procedures, and study visit schedule) and provide reliable and complete data regarding AEs/SAEs and PROs.
  • Have been informed and have given written consent for the use of their data in accordance with local regulations before study inclusion.

Exclusion criteria

Exclusion Criteria:

Participants meeting ANY of the following criteria will be excluded from the study:

  • Women who are pregnant, breastfeeding, or planning to become pregnant during the course of the study.
  • People on vegetarian or vegan diet; People on special diet (e.g. Ducan, Keto, etc.)
  • ≥ 30 kg/m² or \<18.5 kg/m².
  • History of intake of antibiotics, other probiotics, postbiotics, prebiotics, synbiotics, proton pump inhibitors, acid sequestrants (cholestyramine, Bile colestipol), within six months prior to the screening day.
  • Participation in other clinical trials in the last 90 days prior to screening.
  • Allergy to any penicillin antibiotic or any other beta-lactam agent (e.g. cephalosporin, carbapenem or monobactam).
  • History of jaundice/hepatic impairment due to amoxicillin/clavulanic acid.
  • Active smokers or using any form of smokeless tobacco.
  • Participants with substance abuse problems (within two years) defined as:

    • Use of recreational drugs (such as cocaine, methamphetamine, marijuana, etc.)/ Nicotine dependence.
    • High-risk drinking as defined by the consumption of four or more alcohol-containing beverages on any day or eight or more alcohol-containing beverages per week for women and five or more alcohol-containing beverages on any day or 15 or more alcohol-containing beverages per week for men.
  • Participants having illnesses of cardiovascular, endocrine, immune, respiratory, hepato-biliary, kidney and urinary, haematological, musculoskeletal system and/or any inflammatory disorder, tumour, and other gastrointestinal diseases.
  • Participants with a history of bariatric surgery or surgical resection of the stomach, small intestine, or large intestine.
  • Participants actively using GLP1 agonist drugs (Wegovy, Semiglutide etc.) or completed treatment with said medication less than 12 weeks before screening.
  • Any condition that could, in the opinion of the Investigator, preclude the participant's ability to successfully and safely complete the study or that may confound study outcomes.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Prevention
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
126 participants (estimated)

Study arms

  • Experimental
    Probiotic

    Participants in this arm will receive a daily dose of a daily dose of of a probiotic (live bacterium), in a form of 2 capsules once daily, for 28 days.

    Dietary Supplement: Probiotic

  • Experimental
    Postbiotic

    Participants in this arm will receive a daily dose of a postbiotic (heat-inactivated bacterium), in a form of 2 capsules once daily, for 28 days.

    Dietary Supplement: Postbiotic

  • Placebo comparator
    Placebo

    Participants in this arm will receive an equivalent placebo for the duration of the study (28 days).

    Dietary Supplement: Placebo

Interventions

  • Dietary supplementProbiotic

    Participants in this arm will receive a daily dose of of a probiotic (live bacterium), in a form of 2 capsules once daily, for 28 days.

  • Dietary supplementPostbiotic

    Participants in this arm will receive a daily dose of a postbiotic (heat-inactivated bacterium), in a form of 2 capsules once daily, for 28 days.

  • Dietary supplementPlacebo

    Participants in this arm will receive an equivalent placebo for the duration of the study (28 days).

06

What researchers measure

Primary outcomes

  1. Changes in gut microbiome composition between baseline and day 14 as compared to placebo.

    To assess the effects of a probiotic or postbiotic in gut microbiome composition of healthy adults receiving antibiotic therapy, as measured by changes in alpha and beta diversity of the gut microbiome as compared to placebo.

    Time frame: Day 0 and Day 14

Secondary outcomes

  1. Changes in gut microbiome composition throughout the study as compared to placebo and baseline.

    Changes in microbiome composition as measured by changes in alpha and beta diversity of the gut microbiome throughout the study as compared to placebo and baseline.

    Time frame: Day 0, Day 3, Day 7, Day 28, and Day 56

  2. Changes in abundance of beneficial versus opportunistic/ pathogenic bacterial species throughout the study as compared to baseline and to placebo

    Effects of a probiotic or postbiotic on the abundance of beneficial versus opportunistic/pathogenic bacterial species throughout the study as compared to baseline and to placebo.

    Time frame: Day 0, Day 3, Day 7, Day 14, Day 28, and Day 56

  3. Changes in the abundances of microbial genes contained in specific functional modules through the study as compared to baseline and placebo.

    Effects of probiotic or postbiotic on the abundances of genes contained in specific functional modules obtained from KEGG database. A Gene Set Enrichment Analysis (GSEA) is performed to obtain which modules are enriched by the biotics effect thought the study. Significant associations will be reported with the Normalized Enrichment score (NES) and adj.p.value.

    Time frame: Day 0, Day 7, Day 14, Day 28, and Day 56

  4. Study the associations of specific microbe abundances with the development of gastrointestinal (GI) symptoms

    Association between each bacterial abundance and the clinical measures, related to GI symptoms, will be performed using linear models. Significant associations will be reported with the linear model coefficient and adj.p.value.

    Time frame: Day 0, Day 3, Day 7, and Day 14

  5. .Changes in the abundances of microbial virulence factors and antibiotic resistant genes through the study as compared to baseline and placebo.

    Effects of probiotic or postbiotic on the abundances of genes annotated as virulence factors or antibiotic resistant genes through the study as compared to baseline and placebo. The results will be tested using the most fitting statistical method, and p.value will be reported.

    Time frame: Day 0, Day 7, Day 14, Day 28, and Day 56

  6. Safety profile throughout the study as compared to placebo.

    The number of adverse events (AE)/serious adverse events (SAE) related to the study investigational product occurring during the study compared to placebo.

    Time frame: 56 days

  7. Tolerability of a probiotic or postbiotic as measured by a validated questionnaire and compared to placebo.

    Assess tolerability of a probiotic or postbiotic consumption as measured by a validated questionnaire, the Gastrointestinal Symptom Rating Scale (GSRS) throughout the study and compared to baseline and placebo.

    Time frame: Day 0, Day 7, Day 14, Day 28, and Day 56

Other outcomes

  1. Effects on development of antibiotic-associated diarrhea (AAD) as compared to placebo.

    Efficacy of probiotic or postbiotic on incidence of diarrhea or AAD during and after antibiotic therapy as assessed by frequency and form of daily bowel movements measured with Bristol Stool Form Scale (BSFS). BSFS scale ranges from 1 to 7 with scores 1-2 indicating hard and lumpy bowel motions and 6-7 indicating runny, watery stools.

    Time frame: 56 days

  2. Effects on duration of diarrhea or AAD if presented during the study as compared to placebo.

    Efficacy of probiotic or postbiotic on the duration of diarrhea or AAD, if present, as assessed by Bristol Stool Form Scale (BSFS). BSFS scale ranges from 1 to 7 with scores 1-2 indicating hard and lumpy bowel motions and 6-7 indicating runny, watery stools.

    Time frame: 56 days

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Aug 2026 (actual). Primary completion is estimated for May 2027, 9 months after the start.

Of 84 interventional studies with no phase under Dysbiosis, half reached primary completion within 19 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 27. This study's planned 9 months is below that.

Start moved once since we started tracking on Sep 25, 2026: Jun 2026 → Aug 2026, on Oct 28, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Apr 28, 2026
First posted
May 19, 2026
StartActual
Aug 27, 2026was Jun 2026
Primary completionEst.
May 31, 2027
CompletionEst.
May 31, 2027
Last update
Oct 28, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Not yet recruiting→Recruiting
changed Oct 28, 2026
Sites
General Hospital of Thessaloniki Papageorgiou is now Recruiting
Oct 28, 2026
Start date
Jun 1, 2026→Aug 27, 2026 (actual)
Oct 28, 2026
Site contacts
Changed at 1 site. See the sites
Show the site
  • General Hospital of Thessaloniki Papageorgiou · Thessaloniki, GreeceContact m•••@nextcro.eu · •••7282→m•••@nextcro.eu · •••7282
Oct 28, 2026
Show all 1 update
  1. Oct 28, 2026
    Not yet recruiting→Recruiting
    General Hospital of Thessaloniki Papageorgiou is now Recruiting
    Start date Jun 1, 2026→Aug 27, 2026 (now actual)
    Site contacts Changed at 1 site. See the sites
    Show the site
    • General Hospital of Thessaloniki Papageorgiou · Thessaloniki, GreeceContact m•••@nextcro.eu · •••7282→m•••@nextcro.eu · •••7282
    + 1 other change: verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07594860
Lead sponsor
The Archer-Daniels-Midland Company
Collaborators
NEXT CRO
Responsible party
Sponsor
First posted
May 19, 2026
Start date
Aug 27, 2026
Primary completion
May 31, 2027 (estimated)
Completion
May 31, 2027 (estimated)
Last update
Oct 28, 2026

Study contacts

ADM Medical Team
Contact
medical@protexin.com
+441460243230

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Probiotic

Start the discussion